Low CSF somatostatin associated with response to nimodipine in patents with affective illness

Mark A Frye, Peggy J. Pazzaglia, Mark S. George, David A. Luckenbaugh, Elizabeth Vanderham, Candace L. Davis, David R. Rubinow, Robert M. Post

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.

Original languageEnglish (US)
Pages (from-to)180-183
Number of pages4
JournalBiological Psychiatry
Volume53
Issue number2
DOIs
StatePublished - Jan 15 2003
Externally publishedYes

Fingerprint

Nimodipine
Patents
Somatostatin
Cerebrospinal Fluid
Spinal Puncture
Healthy Volunteers
Therapeutics

Keywords

  • Affective illness
  • Cerebrospinal fluid
  • Nimodipine
  • Somatostatin

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Frye, M. A., Pazzaglia, P. J., George, M. S., Luckenbaugh, D. A., Vanderham, E., Davis, C. L., ... Post, R. M. (2003). Low CSF somatostatin associated with response to nimodipine in patents with affective illness. Biological Psychiatry, 53(2), 180-183. https://doi.org/10.1016/S0006-3223(02)01343-4

Low CSF somatostatin associated with response to nimodipine in patents with affective illness. / Frye, Mark A; Pazzaglia, Peggy J.; George, Mark S.; Luckenbaugh, David A.; Vanderham, Elizabeth; Davis, Candace L.; Rubinow, David R.; Post, Robert M.

In: Biological Psychiatry, Vol. 53, No. 2, 15.01.2003, p. 180-183.

Research output: Contribution to journalArticle

Frye, MA, Pazzaglia, PJ, George, MS, Luckenbaugh, DA, Vanderham, E, Davis, CL, Rubinow, DR & Post, RM 2003, 'Low CSF somatostatin associated with response to nimodipine in patents with affective illness', Biological Psychiatry, vol. 53, no. 2, pp. 180-183. https://doi.org/10.1016/S0006-3223(02)01343-4
Frye, Mark A ; Pazzaglia, Peggy J. ; George, Mark S. ; Luckenbaugh, David A. ; Vanderham, Elizabeth ; Davis, Candace L. ; Rubinow, David R. ; Post, Robert M. / Low CSF somatostatin associated with response to nimodipine in patents with affective illness. In: Biological Psychiatry. 2003 ; Vol. 53, No. 2. pp. 180-183.
@article{8c711689040941bf949144e183a96e1e,
title = "Low CSF somatostatin associated with response to nimodipine in patents with affective illness",
abstract = "Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.",
keywords = "Affective illness, Cerebrospinal fluid, Nimodipine, Somatostatin",
author = "Frye, {Mark A} and Pazzaglia, {Peggy J.} and George, {Mark S.} and Luckenbaugh, {David A.} and Elizabeth Vanderham and Davis, {Candace L.} and Rubinow, {David R.} and Post, {Robert M.}",
year = "2003",
month = "1",
day = "15",
doi = "10.1016/S0006-3223(02)01343-4",
language = "English (US)",
volume = "53",
pages = "180--183",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Low CSF somatostatin associated with response to nimodipine in patents with affective illness

AU - Frye, Mark A

AU - Pazzaglia, Peggy J.

AU - George, Mark S.

AU - Luckenbaugh, David A.

AU - Vanderham, Elizabeth

AU - Davis, Candace L.

AU - Rubinow, David R.

AU - Post, Robert M.

PY - 2003/1/15

Y1 - 2003/1/15

N2 - Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.

AB - Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.

KW - Affective illness

KW - Cerebrospinal fluid

KW - Nimodipine

KW - Somatostatin

UR - http://www.scopus.com/inward/record.url?scp=0037439286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037439286&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(02)01343-4

DO - 10.1016/S0006-3223(02)01343-4

M3 - Article

C2 - 12547475

AN - SCOPUS:0037439286

VL - 53

SP - 180

EP - 183

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 2

ER -